Evommune (NYSE:EVMN) Upgraded to Hold at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Evommune (NYSE:EVMN – Free Report) from a sell rating to a hold rating in a research note released on Sunday morning.

A number of other equities research analysts also recently issued reports on EVMN. Cantor Fitzgerald assumed coverage on shares of Evommune in a research report on Monday, December 1st. They set an “overweight” rating for the company. Leerink Partners initiated coverage on Evommune in a research note on Monday, December 1st. They issued an “outperform” rating and a $42.00 price objective for the company. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a research report on Monday, December 1st. Zacks Research upgraded Evommune to a “hold” rating in a research report on Tuesday, December 2nd. Finally, Morgan Stanley initiated coverage on Evommune in a research note on Monday, December 1st. They set an “overweight” rating and a $36.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $39.33.

Get Our Latest Stock Report on Evommune

Evommune Stock Down 8.6%

Shares of EVMN stock opened at $18.00 on Friday. Evommune has a 1-year low of $16.70 and a 1-year high of $24.03.

Evommune (NYSE:EVMN – Get Free Report) last issued its earnings results on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $10.00 million.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.

See Also